Seners P, Baron JC. Revisiting “progressive stroke”: incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke. J Neurol. 2018;265(1):216–25. https://doi.org/10.1007/s00415-017-8490-3.

Article  PubMed  Google Scholar 

Hou X, Chen W, Xu H, Zhu Z, Xu Y, Chen H. The rate of early neurological deterioration occurring after thrombolytic therapy: a meta-analysis. Brain Behav. 2019;9(2): e01210. https://doi.org/10.1002/brb3.1210.

Article  PubMed  PubMed Central  Google Scholar 

Bhole R, Nouer SS, Tolley EA, Turk A, Siddiqui AH, Alexandrov AV, et al. COMPASS investigators. Predictors of early neurologic deterioration (END) following stroke thrombectomy. J Neurointerv Surg. 2023;15(6):584–8. https://doi.org/10.1136/neurintsurg-2022-018844.

Article  PubMed  Google Scholar 

Liu H, Liu K, Zhang K, Zong C, Yang H, Li Y, et al. Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study. Ther Adv Neurol Diso. 2023;16:17562864221147744. https://doi.org/10.1177/17562864221147743.

Article  CAS  Google Scholar 

Jin D, Yang J, Zhu H, Wu Y, Liu H, Wang Q, et al. Risk factors for early neurologic deterioration in single small subcortical infarction without carrier artery stenosis: predictors at the early stage. BMC Neurol. 2023;23(1):83. https://doi.org/10.1186/s12883-023-03128-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farooqui A, Albayram MS, Reddy VBN, Nagaraja N. Neurological deterioration and computed tomography perfusion changes with increased time to peak in lacunar stroke. Brain Circ. 2022;8(1):17–23. https://doi.org/10.4103/bc.bc_68_21.

Article  PubMed  PubMed Central  Google Scholar 

Posadas-Sanchez R, Vargas-Alarcon G. Innate immunity in coronary disease. The role of interleukin-12 cytokine family in atherosclerosis. Rev Invest Clin. 2018;70(1):5–17. https://doi.org/10.24875/RIC.17002335.

Article  CAS  PubMed  Google Scholar 

Pawluk H, Kolodziejska R, Grzesk G, Kozakiewicz M, Woźniak A, Pawluk M, et al. Selected mediators of inflammation in patients with acute ischemic stroke. Int J Mol Sci. 2022;23(18):10614. https://doi.org/10.3390/ijms231810614.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin SY, Wang YY, Chang CY, Wu CC, Chen WY, Liao SL, et al. TNF-alpha receptor inhibitor alleviates metabolic and inflammatory changes in a rat model of ischemic stroke. Antioxidants (Basel). 2021;10(6):851. https://doi.org/10.3390/antiox10060851.

Article  CAS  PubMed  Google Scholar 

Eren F, Yilmaz SE. Neuroprotective approach in acute ischemic stroke: a systematic review of clinical and experimental studies. Brain Circ. 2022;8(4):172–9. https://doi.org/10.4103/bc.bc_52_22.

Article  PubMed  PubMed Central  Google Scholar 

Yang N, Lee H, Wu C. Intravenous thrombolysis for acute ischemic stroke: from alteplase to tenecteplase. Brain Circ. 2023;9(2):61–3. https://doi.org/10.4103/bc.bc_70_22.

Article  PubMed  PubMed Central  Google Scholar 

Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc. 2022;11(3): e023328. https://doi.org/10.1161/JAHA.121.023328.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O’Connor C, Gurbel PA. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016;164(9):600–7. https://doi.org/10.7326/m15-2994.

Article  PubMed  Google Scholar 

Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142(4):419–21. https://doi.org/10.1161/CIRCULATIONAHA.120.046320.

Article  PubMed  PubMed Central  Google Scholar 

Stein E, Wasserman SM, Dias C, Scott R, Raal FJ. AMG-145, evolocumab. Drugs Future. 2013;38:451–9. https://doi.org/10.1358/dof.2013.038.07.1981967.

Article  Google Scholar 

Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol. 2017;2(5):556–60. https://doi.org/10.1001/jamacardio.2016.5395.

Article  PubMed  PubMed Central  Google Scholar 

Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke. 1999;30(12):2631–6. https://doi.org/10.1161/01.str.30.12.2631.

Article  PubMed  Google Scholar 

Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, et al. Effect of alirocumab on stroke in ODYSSEY outcomes. Circulation. 2019;140(25):2054–62. https://doi.org/10.1161/circulationaha.119.043826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke. 2020;51(5):1546–54. https://doi.org/10.1161/STROKEAHA.119.027759.

Article  CAS  PubMed  Google Scholar 

Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Robert Roberts R, Quyyumi AA, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE. 2014;9(9): e106294. https://doi.org/10.1371/journal.pone.0106294.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Liu J, Li S, Sun J, Tang Y, Li JJ. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192. https://doi.org/10.1186/1471-2261-14-192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New Engl J Med. 2015;372(16):1500–9. https://doi.org/10.1056/NEJMoa1500858.

Article  CAS  PubMed  Google Scholar 

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598–607. https://doi.org/10.1001/jamacardio.2017.0747.

Article  PubMed  PubMed Central  Google Scholar 

Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, et al. 2019 ESC/EAS guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):324–33. https://doi.org/10.1093/ehjcvp/pvaa077.

Article  PubMed  Google Scholar 

Ou Z, Yu Z, Liang B, Zhao L, Li J, Pang X, et al. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients. Front Cardiovasc Med. 2022;9: 939791. https://doi.org/10.3389/fcvm.2022.939791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis. 2015;242(2):490–5. https://doi.org/10.1016/j.atherosclerosis.2015.08.005.

Article  CAS